Saturn V Capital Management LP - Q1 2023 holdings

$134 Million is the total value of Saturn V Capital Management LP's 18 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 22.2% .

 Value Shares↓ Weighting
MORF SellMORPHIC HOLDING INC$9,282,626
+25.9%
246,616
-8.6%
6.93%
+13.3%
APLS SellAPELLIS PHARMACEUTICALS INC$8,123,963
-13.7%
123,165
-42.0%
6.07%
-22.3%
SAGE SellSAGE THERAPEUTICS INC$6,084,955
+13.4%
145,018
-7.1%
4.54%
+2.0%
FOLD SellAMICUS THERAPEUTICS INC(NMS)$2,864,414
-41.5%
258,288
-54.4%
2.14%
-47.3%
ARQT SellARCUTIS BIOTHERAPEUTICS INC$1,960,387
-77.7%
178,217
-63.4%
1.46%
-79.9%
Sell2SEVENTY BIO INC$1,756,318
-82.2%
172,188
-74.9%
1.31%
-84.0%
SellASTRIA THERAPEUTICS INC$1,347,809
-13.4%
101,339
-40.2%
1.01%
-22.1%
TBPH ExitTHERAVANCE BIOPHARMA INC$0-141,339
-100.0%
-1.11%
ALBO ExitALBIREO PHARMA INC$0-341,827
-100.0%
-5.70%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
CRINETICS PHARMACEUTICALS IN4Q3 202314.0%
CYMABAY THERAPEUTICS INC4Q3 202310.6%
CYTOKINETICS INC4Q3 20237.4%
KALVISTA PHARMACEUTICALS INC4Q3 20237.3%
HORIZON THERAPEUTICS PUB L4Q3 20238.1%
BIOGEN INC(NSM)4Q3 20237.8%
ASCENDIS PHARMA A/S - ADR4Q3 20236.6%
ITEOS THERAPEUTICS INC4Q3 20235.8%
MORPHIC HOLDING INC4Q3 20236.9%
BIOCRYST PHARMACEUTICALS INC4Q3 20237.2%

View Saturn V Capital Management LP's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G2024-02-12
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-09

View Saturn V Capital Management LP's complete filings history.

Export Saturn V Capital Management LP's holdings